Identification of tRNA-Related Fragments and Their Potential Regulatory Effects in Thyroid-Associated Ophthalmopathy

被引:2
|
作者
Yue, Zifan [1 ]
Tong, Fei [1 ]
Zeng, Chengcheng [1 ]
Wei, Ruili [1 ]
机构
[1] Navy Mil Med Univ, Dept Ophthalmol, Changzheng Hosp, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
thyroid-associated ophthalmopathy; microRNA; tRNA-related fragments; messenger RNA; RNA sequencing; GRAVES ORBITOPATHY; PATHOGENESIS; DISEASE; EXPRESSION; CANCER; VEGF; TEPROTUMUMAB; TRANSLATION; METASTASIS; TARGETS;
D O I
10.3389/fgene.2022.878405
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Recently, the potential role of tRNA-related fragments (tRFs) in ophthalmic diseases has been extensively researched. However, systematic studies on the potential regulatory effects of tRFs in thyroid-associated ophthalmopathy (TAO) are lacking. We used high-throughput sequencing techniques to measure expression levels of mRNAs and tRFs in patients with TAO, and the results were verified by real-time quantitative reverse transcription polymerase chain reaction (q-PCR). Next, the potential biological regulatory effect of differentially expressed tRFs was analyzed, and potential downstream target RNAs of differentially expressed tRFs were predicted to explore the potential role of tRFs as therapeutic targets and biomarkers of TAO. A total of 50 tRFs and 361 mRNAs were dysregulated in the TAO group, and tRF5-GluCTC, PMAIP1, HSD17B2 and ATF3 were verified to be significantly differentially expressed in TAO. Our research reveals that several associated pathways likely play a role in the pathogenesis of TAO. By targeting ATF3, HSD17B2 and PMAIP1, tRF5-GluCTC may play a potential role in regulating the orbital fibroblast adipogenic response and fibrotic hyperplasia in patients with TAO.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] THYROID-ASSOCIATED OPHTHALMOPATHY
    WEETMAN, AP
    AUTOIMMUNITY, 1992, 12 (03) : 215 - 222
  • [2] Defective Regulatory B Cells Are Associated With Thyroid-Associated Ophthalmopathy
    Chen, Guo
    Ding, Yungang
    Li, Qian
    Li, Yanbing
    Wen, Xiaofeng
    Ji, Xian
    Bi, Shaowei
    Chen, Jingqiao
    Xu, Jianan
    Chen, Rongxin
    Ye, Huijing
    Wei, Lai
    Yang, Huasheng
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (09): : 4067 - 4077
  • [3] SINUSITIS IN THYROID-ASSOCIATED OPHTHALMOPATHY
    DAVRIS, S
    RIECHELMANN, H
    MANN, W
    KAHALY, G
    AMERICAN JOURNAL OF RHINOLOGY, 1993, 7 (05): : 233 - 235
  • [4] Progress in thyroid-associated ophthalmopathy
    Hiromatsu, Y
    Wall, JR
    THYROID, 2002, 12 (03) : 185 - 185
  • [5] Rituximab for thyroid-associated ophthalmopathy
    Minakaran, Neda
    Ezra, Daniel G.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (05):
  • [6] PATHOGENESIS OF THYROID-ASSOCIATED OPHTHALMOPATHY
    PERROS, P
    KENDALLTAYLOR, P
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1993, 4 (08): : 270 - 275
  • [7] THE PATHOGENESIS OF THYROID-ASSOCIATED OPHTHALMOPATHY
    PERROS, P
    KENDALLTAYLOR, P
    JOURNAL OF ENDOCRINOLOGY, 1989, 122 (03) : 619 - 624
  • [8] Progress in thyroid-associated ophthalmopathy
    Wall, J
    Kennerdell, JS
    AUTOIMMUNITY, 1995, 22 (03) : 191 - 195
  • [9] GLYCOSAMINOGLYCANS IN THYROID-ASSOCIATED OPHTHALMOPATHY
    KAHALY, G
    STOVER, C
    OTTO, E
    BEYER, J
    SCHULER, M
    AUTOIMMUNITY, 1992, 13 (01) : 81 - 88
  • [10] Rituximab for thyroid-associated ophthalmopathy
    Kang, Swan
    Azzam, Shirin Hamed
    Minakaran, Neda
    Ezra, Daniel G.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (06):